About

Using generative biology and chemistry, we are revolutionizing the speed and accuracy of how medicine is created.

Our Hyperloop^® Platform combines deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure to create candidate-ready compounds with unprecedented speed.

Our Core Values:

Urgency: We move swiftly and purposefully to address critical unmet patient needs.
Resilience: We persist in the face of challenges, turning setbacks into opportunities.
Collaboration: We build strong partnerships and value diverse perspectives.
Transparency: We build trust through openness, directness, and accountability.
Compassion: We lead with empathy, always keeping patients at the heart of our mission.

Investors

Staff

Aaron Plys

Principal Scientist, Biology

Ajay Yekkirala

Chief Scientific Officer

Alix Rouault

Sr. Scientist, Pharmacology

Amanda Iskandar

Associate Director, Program Management

Andrew Little

Principal Scientist, Medicinal Chemistry

Anuj Kumar

Vice President, CMC

Arielle Young

Executive Assistant

Cameron Russell

Senior Research Associate, Biology

Carrie Kolmer

Director, Head of Financial Planning & Analysis

Cheri Ross

Sr. Scientist, Lead Generation

Chris Oalmann

Vice President, Head of LEADs

Chris Quimby

Facilities Manager

Colin Gauvin

Sr. Scientist, Protein Design & Structure

Cony D’Cruz

Chief Executive Officer

Dilinie Fernando

Principal Scientist, Medicinal Chemistry

Elaine Krueger

Vice President, Head of IDEAs

Elena Longhi

Sr. Scientist, Lead Generation

Emily Longo

Senior Research Associate, Discovery Biology

Eric Sanford

Scientist II, Biology

Erin Burry

Accounting Manager

Fernando Terrero

Senior Manager, Talent Acquisition

Florentina Tofoleanu

Associate Director, Computational Chemistry

Galip Yiyen

Lab Technician, Protein Design & Structure

Haoxuan Wang

Sr. Scientist, Lead Generation

Heather Davis

Associate Director, Program Management

Heike Schoenherr

Sr. Director, Head of Lead Generation

Hongtao Zeng

Principal Scientist, Discovery Biology

Jacob Jensen

Senior Research Associate, Biology

Jasmine Nguyen

Lab Operations Manager

Jenny Herman

Senior Vice President, Finance

Jill Sutt

Executive Director, Clinical Development & Operations

Jordan Torpey

Office Manager

Katelyn Billings

Chief of Staff, Head of Program and Alliance Management

Kayla Tift

Director, Business Operations

Kelley Shortsleeves

Principal Scientist, Lead Generation

Ken Borrelli

Sr. Director, Head of Computation

Liz Yurkewych

Staff Engineer, Research Informatics and AI

Malina Martinez

Director, Technical Accounting & Financial Reporting

Mark Fitzgerald

Director, Medicinal Chemistry

Mark Moran

Senior Scientist, Compound Management

Maureen Eron

Principal Scientist, Exploratory Biology

Melanie Chien

Senior Research Associate, Biology

Michael Robertson

Associate Director, Protein Design & Structure

Min-Sun Park

Associate Director, Computational Chemistry

Mira Khazanchi

Research Associate, Biology

Molly Premtoon

Principal Scientist, Computational Chemistry

Murco Ringnalda

Chief Financial Officer

Neil Lajkiewicz

Associate Director, Medicinal Chemistry

Nikita Subramanian

Vice President, Human Resources

Olivia Pierce

Director, Computational Chemistry

Oluyinka Green

Associate Director, Patent Agent

Reilly Osadchey

Engineer II, Machine Learning

Rulin Ma

Principal Scientist, Medicinal Chemistry

Ryan Bloom

Senior Vice President, Business Development and Operations

Sachin Samuchiwal

Associate Director, Pharmacology

Sam Malekiani

Associate Vice President, Toxicology

Samantha Figueroa

Specialist II, Business Operations

Shivani Sharma

Scientist, Protein Design & Structure

Steven Arkin

Chief Medical Officer

Sujatha Kumar

Vice President, Head of BRIDGE

Theresa Baker Tran

Sr. Lab Scientist, Biology

Unnati Pandya

Principal Scientist, Biology

Victoria Brown

Associate Director, Biology

Xin Sun

Director, Head of Biology

Yung-Chi Huang

Sr. Scientist, Biology

Zhonghui Xu

Senior Engineer, Machine Learning

Join Our Team

Join us to accelerate new possibilities in drug discovery.

Scientific Advisory Board

Carrie Haskell-Luevano, PhD

Philip S. Portoghese Endowed Chair in Chemical Neuroscience
Institute for Translational Neuroscience Scholar
Department of Medicinal Chemistry, University Of Minnesota

Georgia McGaughey, PhD

Trilligant LLC, Founder

John Griffin, PhD

Morris J. Birnbaum, MD PhD (Chair)

Professor Emeritus, University of Pennsylvania

Sandeep Menon, MD, PhD

Chief Research & Development Officer, BioCryst Pharmaceuticals

Terry Kenakin

Professor, Department of Pharmacology
University of North Carolina- School of Medicine

Board of Directors

Cony D’Cruz

Chief Executive Officer - Superluminal Medicines

Diamantis Xylas, MD

Partner & Head of Research - Catalio Capital Management, LP

Dylan Morris

Managing Director- Insight Partners

Harsha Paladugu

Analyst at BVF Partners

Nandita Shangari

Managing Director- RA Capital Management

Willard Dere

Professor Emeritus, University of Utah School of Medicine

News & Insights

View All Posts

Published September 2026

Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic

Published August 2025

“Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss.” Featured Story on Endpoints News by Kyle LaHucik

Published August 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

Science

Our Hyperloop® Platform unites novel structure-based drug discovery with AI-driven computational approaches and experimental readouts to discover and validate small molecule therapeutics.

Our Platform

Pipeline

With an initial focus on GPCRs, our pipeline combines scientific ingenuity with patient-focused precision, developing next-generation treatments for cardiometabolic diseases.

Our Pipeline